Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Leuk Lymphoma. 2009 Nov;50(11):1865–1871. doi: 10.3109/10428190903221010

Figure 2.

Figure 2

Expression of hsa-miR-193b and hsa-miR-365 in purified CD138 positive cells from 10 MM patients determined by Q-PCR. The data are shown as fold change in expression of hsa-miR-193b and hsa-miR-365 compared to expression levels observed in purified CD138 positive cells of two pooled healthy donors. Q-PCR was done in triplicate and data were calculated using the comparative Ct (2−ΔΔCt) method. U6 snRNA was used as an internal control. All Q-PCR data were statistically significant (*P<0.05). The P values of hsa-miR-193b and hsa-miR-365 for each myeloma patient sample were 0.008 and 0.005 (MM pt1), 0.014 and 0.015 (MM pt2), 0.023 and 0.047 (MM pt3), 0.016 and 0.032 (MM pt4), 0.046 and 0.002 (MM pt5), 0.004 and 0.001 (MM pt6), 0.034 and 0.036 (MM pt7), 0.014 and 0.029 (MM pt8), 0.007 and 0.003 (MM pt9), 0.038 and 0.044 (MM pt10) respectively. The mean signal intensities for hsa-miR-193b in myeloma patient samples and healthy donors were 429 and 157 respectively. The mean signal intensities for hsa-miR-365 in myeloma patient samples and healthy donors were 351 and 135 respectively.